A study to observe and assess the safety and efficacy of Unani regimen in preventing the progression of severity of asymptomatic mild to moderate symptomatic cases.

A prospective, interventional, case control study to observe and assess the safety and efficacy of Unani regimen in preventing the progression of severity of the disease in hospitalized SARS-CoV2 tested positive asymptomatic /mild to moderate symptomatic COVID-19 cases, managed as per Govt of India COVID-19 management guidelines, at a COVID-19 management facility

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2020/07/026462

Enrollment

124

Registered

2020-07-09

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere

Interventions

Intervention1: Khameera Marvareed: 5 g once daily, Orally for 14 days along with the standard care of treatment as recommended by MOHFW guidelines for COVID-19 patient care Intervention2: Unani Joshan

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients of either sex aged between 18-65 years 2. Patients who have been tested positive with SARS-CoV2 virus Asymptomatic Patients or Patients with mild symptoms or Patients with moderate symptoms with respiratory rate saturation > 90% 3. Voluntariness to participate in the trial USCDC classification mild to moderate, severe and critical stages of COVID-19 Stage Features Asymptomatic No specific clinical symptoms of COVID-19 disease Mild to Moderate Mild clinical symptoms up to mild pneumonia Severe Dyspnea, hypoxia, or >50% lung involvement on imaging Critical Respiratory failure, shock, or multiorgan system dysfunction

Exclusion criteria

Exclusion criteria: The subject must be excluded from participating in the trial if they fulfill anyone of the criteria as mentioned below: 1. COVID-19 patients with symptoms classified as severe or critical. 2. Suspected COVID-19, not tested positive for COVID-19 by RT-PCR 3. Persons with severe primary respiratory disease or pneumonia 4. Pregnant and lactating women 5. Persons with serious diseases such as Cancer, Heart Disease, Stroke, Disabilities, Mental illnesses, etc., and who are considered to be excluded from the study as evaluated by the investigators 6. COVID-19 positive cases participating as subjects in the interventional arm of other COVID-19 clinical trials

Design outcomes

Primary

Measure	Time frame
Time taken to get COVID-19 RT-PCR test negative. Incidence of patients progressing to next stage with regards to severityTimepoint: 14 days	—

Secondary

Measure	Time frame
Duration of subsidence of fever, respiratory and other COVID-19 symptomsTimepoint: 14days	—

Countries

India

Contacts

Public ContactDr Nauman Saleem

Central Council for Research in Unani Medicine (CCRUM)

usamakramdr@gmail.com9540606010

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026